Trial: 201807178

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment


II/III (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Other Hematopoietic

Learn more about this study at: